Article Figures & Data
Figures
- FIGURE 1.
Form used to determine whether patient can be released from hospital after radioimmunotherapy with 131I-anti-B1 antibody. S/N = serial number.
Tables
Patient no. Total body dose (cGy) Administered activity (GBq) Teff (tracer) (h) Initial patient dose rate (mSv/h) Dosimeter* readings (mSv) Direct reading Days TLD or OSL Days 1 65 3.85 54.8 0.14 0.37 3.8 0.70 12.3 2 45 1.67 72.1 NA 0.61 9 0.50 9 3 65 1.48 85.2 NA — — 1.70 17 4 30 1.54 63.6 0.09 1.46 7 1.20 8 5 30 1.14 71.0 0.06 0.38 6 0.39 6 6 30 1.26 64.0 0.04 0.79 6.2 1.05 11 7 75 3.06 75.6 0.14 1.31 4.2 1.71 6 8 75 4.25 56.3 0.14 1.68 7 2.35 7 9 45 2.15 62.9 0.05 0.51 5.1 0.71 5.1 10 45 2.70 52.9 0.08 0.10 3.1 0.17 3.1 11 45 0.94 80.3 0.03 0.68 3 0.79 3 12 60 1.74 71.3 0.09 1.27 9 — — 13 60 2.27 62.5 0.09 0.56 5.8 — — 14† 60 3.26 67.6 0.14 2.28 5.9 3.45 5.9 15† 60 2.24 69.4 0.08 3.54 17 4.09 17 16 60 3.57 59.4 0.18 1.21 5 1.31 5 17 60 2.48 62.0 0.11 0.51 5 — — 18 75 3.92 67.0 0.12 1.21 6.3 — — 19 75 3.86 45.5 0.10 0.80 2.1 — — 20 75 1.76 77.4 0.08 2.17 13 — — 21 75 3.58 73.0 0.13 1.81 7 — — 22 75 4.77 67.9 0.16 1.15 6 — — High 75 4.77 85 0.18 3.54 17 4.09 17 Low 30 0.94 46 0.03 0.10 2.1 0.17 3 Average 58 2.61 66 0.10 1.16 6.5 1.44 8.2 ↵* MyDose electronic pocket dosimeter (Aloka Co., Ltd., Tokyo, Japan) used for direct readings. Film badge, TLD, or OSL dosimeter used for verification.
↵† Radiation badge shared by >1 individual (e.g., family member) to conservatively determine radiation dose to maximally exposed individual.
NA = patients who were released on basis of administered activity (no dose rates were recorded); — = dosimeter was not provided.
Patient no. Predicted dose for infinite time Measured dose for infinite time based on dosimeter readings (Eq. 6) Using Equation 1 (administered activity) Using Equation 2 (patient dose rate and 8-h nonvoiding) Using Equation 5 (patient dose rate and 3-h nonvoiding) 1 6.02 3.89 3.05 0.72 2 3.20 NA NA 0.70 3 3.25 NA NA 1.76 4 2.68 2.65 2.24 1.74 5 2.17 1.94 1.65 0.52 6 2.21 1.21 0.95 1.11 7 6.11 4.80 4.09 2.33 8 6.77 4.03 3.12 2.69 9 3.72 1.54 1.14 0.96 10 4.11 2.13 1.58 0.27 11 1.97 1.22 1.02 1.71 12 3.32 2.77 2.35 1.45 13 3.92 2.64 2.13 0.71 14 5.96 4.44 3.69 4.51* 15 4.19 2.64 2.16 4.16* 16 5.92 4.97 4.10 1.74 17 4.25 3.26 2.68 0.60 18 7.13 3.94 3.14 1.53 19 5.29 2.62 1.85 1.49 20 3.57 2.80 2.39 2.31 21 6.96 4.45 3.68 2.27 22† 8.76 5.24 4.23 1.49 Group Dose for infinite time High Low Average Median All patients Predicted using Equation 1 8.76 1.97 4.61 4.15 Predicted using Equation 2 5.24 1.21 3.12 2.78 Predicted using Equation 5 4.23 0.95 2.54 2.37 Based on measurements 4.51 0.27 1.68 1.51 75-cGy patients Predicted using Equation 1 8.76 3.57 6.37 6.77 Predicted using Equation 2 5.24 2.62 3.98 4.03 Predicted using Equation 5 4.23 1.85 3.21 3.14 Based on measurements 2.69 1.49 2.02 2.27 Data are in millisieverts.
- TABLE 4
Comparison of Measured Dose for Infinite Time vs. Predicted Dose for Infinite Time
Group Comparison of measured vs. predicted doses for infinite time High Low Average All patients Using Equation 1 98 4 32 Using Equation 2 155 8 47 Using Equation 5 189 47 58 75-cGy patients Using Equation 1 65 17 35 Using Equation 2 83 29 53 Using Equation 5 97 35 67 Data are percentages calculated by dividing measured dose for infinite time by predicted dose for infinite time and multiplying by 100.
In this issue
Jump to section
Related Articles
Cited By...
- Bexxar(R): Novel Radioimmunotherapy for the Treatment of Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma
- Techniques for Using Bexxar for the Treatment of Non-Hodgkin's Lymphoma*
- Radiolabeled Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoma
- A Practical Methodology for Patient Release After Tositumomab and 131I-Tositumomab Therapy
- Hospital Discharge of Patients with Thyroid Carcinoma Treated with 131I
- Investigation of Patient Release Criteria